Half-year report January-June 2007

2007-07-13 - 11:15

• Net sales increased by 10 percent to SEK 96.8 (88.4) million. Adjusted for exchange rate effects, the increase was 13 percent. During the second quarter sales amounted to SEK 47.5 (42.5) million, corresponding to an increase of 12 percent.

• Gross income increased by 13 percent to SEK 67.0 (59.2) million, and the gross margin improved to 69 percent (67). Gross income for the second quarter increased by 14 percent to SEK 33.3 (29.1) million and the gross margin was 70 (69) percent.

• Operating income increased by 44 percent and amounted to SEK 13.8 (9.6) million, which gives an operating margin of 14 percent (11). For the second quarter operating income amounted to SEK 5.9 (4.2) million.

• Operating income before research and development costs increased by 25 percent to SEK 27.0 (21.6) million. This corresponds to a margin of 28 percent (24). For the second quarter the increase was 22 percent to SEK 12.4 (10.2) million, a margin of 26 percent (24).

• Continued strong focus on research and development activities, 13.6 percent (13.6) of sales, 13.8 percent (14.3) for the second quarter.

• Consolidated net income increased to SEK 20.5 (7.1) million. Capitalization of the deferred tax asset in loss carry-forward for tax purposes has been carried out to the tune of SEK 8.2 (-) million. The figures for the second quarter were SEK 9.5 (2.8) million and SEK 4.1 (-) million, respectively.

• The cash flow from operating activities increased to SEK 12.3 (8.5) million, of which SEK 7.3 (8.0) was for the second quarter.

• Earnings per share increased to SEK 1.04 (0.36) of which SEK 0.48 (0.14) was for the second quarter.

• The equity/assets ratio amounted to 83 percent (78).

• Launch of a new product series within Fertility, the G5 Series™, was begun after the end of the period.

• New agreement with Cellartis within the development of new stem cell media.


July 13, 2007
Kungsbacka, Sweden

The Board and the CEO




Queries should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.